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Abstract
Dendritic hPG-amid-C18-mPEG core-multishell nanocarriers (CMS) represent a novel class of unimolecular micelles
that hold great potential as drug transporters, e.g., to facilitate topical therapy in skin diseases. Atopic dermatitis is
among the most common inflammatory skin disorders with complex barrier alterations which may affect the
efficacy of topical treatment.
Here, we tested the penetration behavior and identified target structures of unloaded CMS after topical
administration in healthy mice and in mice with oxazolone-induced atopic dermatitis. We further examined whole
body distribution and possible systemic side effects after simulating high dosage dermal penetration by
subcutaneous injection.
Following topical administration, CMS accumulated in the stratum corneum without penetration into deeper viable
epidermal layers. The same was observed in atopic dermatitis mice, indicating that barrier alterations in atopic
dermatitis had no influence on the penetration of CMS. Following subcutaneous injection, CMS were deposited in
the regional lymph nodes as well as in liver, spleen, lung, and kidney. However, in vitro toxicity tests, clinical data,
and morphometry-assisted histopathological analyses yielded no evidence of any toxic or otherwise adverse local
or systemic effects of CMS, nor did they affect the severity or course of atopic dermatitis.
Taken together, CMS accumulate in the stratum corneum in both healthy and inflammatory skin and appear to be
highly biocompatible in the mouse even under conditions of atopic dermatitis and thus could potentially serve to
create a depot for anti-inflammatory drugs in the skin.
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Background
Topical application of drugs to the skin for direct delivery
to the epidermis or dermis is often highly desirable for the
treatment of skin diseases. Nanosized drug delivery
systems, collectively termed nanocarriers, have recently
gained large interest for their potential to optimize this
topical delivery. Polymeric dendritic core-multishell
nanocarriers were specifically designed for this task and
have proven promising in several previous in vitro studies.
They consist of a core molecule, such as hyperbranched
polyglycerol, to which amphiphilic side chains are
covalently bound. The part of the side chains bound to
the core, for example an alkane chain, creates a lipophilic
inner shell and the outer part, e.g., polyethylene glycol, a
hydrophilic outer shell or vice versa [1–4]. Consequently,
their architecture effectively renders them a unimolecular
equivalent to a micelle or, more correctly, a liposome. The
rationale of creating such a molecule is to combine the
ability of a micelle to transport both hydrophilic and lipo-
philic molecules as a universal carrier with the stability of
a single molecule that does not disintegrate below a crit-
ical micellar concentration [3, 5].
The prototype and most investigated substance of this
class of nanocarriers is the hPG-amid-C18-mPEG-core-
multishell-nanocarrier, from here on referred to as CMS.
Recent in vitro and ex vivo studies have shown that
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CMS may increase the penetration of cargo compounds
through the stratum corneum into the viable epidermis
and even into the dermis, potentially even more effect-
ively than the more established class of solid lipid nano-
particles under the same conditions [6–8]. However,
studies on the skin penetration behavior of the carrier it-
self in various in vitro and ex vivo models have yielded
controversial results [8] and CMS have not yet been in-
vestigated in vivo.
Furthermore, as nanocarriers may be specifically
intended to be applied to diseased skin, it is imperative
to establish whether alterations of the skin barrier under
conditions of disease may change the penetration behav-
ior of the particles [9]. An increased penetration into
diseased skin would require a more severe scrutiny of
local and systemic biosafety issues. On the other hand,
such an effect could be potentially exploited for deliver-
ing a larger amount of drug to lesional skin than to the
adjacent healthy skin. Indeed, recent in vitro data have
suggested that CMS may exhibit increased penetration
in several models of altered skin barrier function [6];
however, they have not yet been investigated on diseased
skin in vivo.
Atopic dermatitis (AD) is a prime example of a com-
mon skin disease with potentially altered skin barrier
function that may benefit from nanocarrier formulations.
AD is among the most common inflammatory skin dis-
eases in humans worldwide, affecting up to 25% of chil-
dren and up to 3% of adults [10, 11]. The condition is
clinically characterized by highly pruritic, erythematous,
and often excoriated plaques [11, 12]. It is a chronic
condition and typically requires long-term treatment
with topical anti-inflammatory drugs. In AD, epidermal
cornification, differentiation, and possibly lipid compos-
ition are thought to be altered. The resulting complex
disturbances of skin barrier function are still poorly
understood, but may allow for enhanced outside-to-
inside penetration of antigens [13–17] as well as poten-
tially drugs [18], possibly including nanoparticles under
certain conditions [19]. To this date, the penetration of
CMS through AD skin has not been investigated in vivo,
as is true for most other nanoparticles.
Here, we investigated the penetration of CMS as a
prototype of the novel class of dendritic core-multishell
nanocarriers into normal mouse skin and a mouse
model of AD. The oxazolone-induced mouse model dis-
plays structural barrier alterations and clinical signs
highly similar to human AD [20]. We hypothesized that
CMS would not penetrate into healthy skin but may
show increased penetration through the inflamed AD
skin. In addition to standard microscopy, we employed a
novel approach using fluorescence lifetime imaging mi-
croscopy (FLIM) to obtain a more detailed insight into
the CMS distribution in the skin and beyond, based on
the sensitivity and uniqueness of fluorescence decay
curves [21]. Furthermore, local and systemic effects of
topical CMS application were examined, complemented
by in vitro toxicity assays. Finally, we asked in which or-
gans CMS would be deposited and whether CMS could
potentially induce any adverse systemic effects in case of
full penetration through a diminished skin barrier by
mimicking such a penetration using subcutaneous injec-
tion of the full dose that would be typically applied
topically.
Methods
Particle Synthesis and Characterization
CMS were synthesized and labeled with the fluorescent
dye indocarbocyanine (ICC) basically as described earlier
[1], with minor modifications, see Additional file 1,
resulting in the empirical formula hPG10000[-NH2-
ICC0.02(C18-mPEG350)0.98]0.7 (CMS-ICC). Dynamic
light scattering [7] revealed a mean particle diameter of
12.4 ± 3.5 nm.
Animals and Study Protocol
The study protocol was approved by the State Office of
Health and Social Affairs, Berlin, Germany (LaGeSo; G
0126/13) and performed according to national guide-
lines. All substance applications and measurements of
clinical parameters were conducted under isoflurane
anesthesia. Mice lay on a heating mat during all
procedures.
Induction of Atopic Dermatitis Model
AD was induced via repeated topical hapten challenges
with oxazolone (OX, Sigma-Aldrich, St. Louis, USA) in
6- to 8-weeks-old, male, hairless SKH-1 mice (Charles
River, Sulzfeld, Germany) as described [20] with minor
modifications. Briefly, mice were sensitized with 5% OX
on a 1.5 × 1.5 cm area of the right flank, followed by
repeated challenges with 0.1% OX as described in
Additional file 2.
Topical Application of Nanocarriers
CMS-ICC (44.5 μl, 5 g/l) in 0.9% sodium chloride (NaCl)
solution or the solvent alone were topically applied twice
daily for five consecutive days to the right flank of
healthy mice or the inflamed skin area of the AD model
(Table 1, Additional file 2: a, b). Topically applied
substances were massaged for 3 min and allowed to dry
and seep in for 1 h prior to termination of the
anesthesia.
Subcutaneous Injection of Nanocarriers
To mimic a complete transepidermal uptake, CMS-ICC in
0.9% NaCl solution (150 μl, 5 g/l, i.e., approx. 30 mg/kg
body mass) or vehicle only were subcutaneously injected
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into the right flank of an additional group of SKH-1 mice
twice daily for five consecutive days (Table 1, Additional
file 2: c).
Measurement of Clinical Parameters
During the entire experiment, mice were clinically exam-
ined and the dermatologic standard parameters of trans-
epidermal water loss (TEWL), erythema index, and skin
hydration were quantified prior to each substance
application.
Sacrifice and Sampling
Approximately 16 h after the respective last treatment,
animals were sacrificed by isoflurane overdose and tis-
sues were sampled and processed as described [22].
Particle Localization via Fluorescence Microscopy and
Fluorescence Lifetime Imaging Microscopy
The distribution of CMS-ICC was evaluated via a fluor-
escence microscope on formalin-fixed, paraffin-
embedded, 4′,6-diamidino-2-phenylindole (DAPI) coun-
terstained sections from all tissues in groups 1, 3, and 5
(Table 1) while the respective vehicle treated groups 2, 4,
and 6 served as negative controls as previously described
[22]. Additionally, selected sections of the skin (groups 1
to 4) were analyzed by FLIM [21] to confirm the findings
from conventional microscopy with increased specificity.
In particular, FLIM allows to better differentiate between
low level specific signals and autofluorescent tissue back-
ground. Increased specificity is based on CMS-ICC exhi-
biting a fluorescence decay curve that is very distinct
from all autofluorescent substances observed in the skin
samples (Fig. 1g, j). The setup consisted of an inverted
microscope (Olympus IX71) equipped with a ×60 water
objective (Olympus UPLSAPO 60XW; NA: 1.2), a con-
focal laser galvanometer scanning unit (DCS-120, Becker
& Hickl, Berlin, Germany), and a picosecond tunable
white light supercontinuum laser source in combination
with an acousto-optical tunable filter (SuperK Extreme
EUV3 and SELECT UV-VIS, NKT Photonics) [23]. Par-
affin sections of healthy and atopic murine skin were
measured through 0.13–0.15-mm-thick cover glass.
CMS-ICC- and vehicle control (NaCl-solution)-treated
skin was excited at 530 nm (0.22 mW) with a pulse
repetition rate of 19.5 MHz. The resulting fluorescence
emission was collected for 900 s and spectrally selected
by a long-pass filter (575 LPET, Chroma). The ratio of
the stop⁄start pulse rate was normally less than 200:1, ap-
propriate for time correlated single photon counting
(TCSPC) [24]. The fluorescence decay traces in each
image pixel were detected in 1024 channels with a chan-
nel width of 19.5 ps by a hybrid photomultiplier tube
(HPM-100-40, Becker & Hickl) and a TCSPC module
(SPC-160; Becker & Hickl). The instrument response
function of the system was less than 100 ps full width at
half maximum. FLIM data were analyzed using self-
written routines in C++. Fluorescence decay traces of
the individual pixels were partitioned into classes (i.e.,
clusters) using a multivariate pattern recognition
method. False-color images were generated by assigning
a distinct color to all pixels containing a fluorescence
decay curve that belongs to a certain cluster. To adjust
the fluorescence excitation intensity to the different
amounts of CMS-ICC fluorescence in the skin, images
were taken subsequently for the upper and lower epider-
mis and analyzed together.
Histopathologic and Digital-Morphometric Analyses
Mouse organs were examined histopathologically by vet-
erinary pathologists (MR, HP, LM) using formalin-fixed,
paraffin-embedded sections stained with hematoxylin
and eosin (H&E). Tissues and organs examined included
treated skin, untreated skin (contralateral flank), inguinal
lymph nodes, axillar lymph nodes, accessory axillar
lymph nodes, spleen, liver, lung, brain, thymus, heart,
stomach, small and large intestine, mesenterial lymph
nodes, pancreas, thyroid glands, adrenal glands, kidneys,
testicles, and bone marrow. Relevant dermal inflamma-
tory parameters were quantified via an observer-blinded
analysis. The thickness of H&E stained epidermis was
measured without the stratum corneum on 66 randomly
chosen areas between the hair follicles on scanned slides
using digital image analysis software (Image Scope,
Aperio Technologies, version 10.2.). Mast cells stained
with toluidine blue and eosinophils stained with congo
red were counted as described [25]. CD3+ T lympho-
cytes were labeled immunohistochemically and quanti-
fied as described [25].
In Vitro Toxicological Analyses
Cell viability, cytotoxicity, apoptotic activity, and oxida-
tive stress were analyzed in human immortalized kerati-
nocytes (HaCaT cells) after exposure to 50, 100, 200,
500, or 700 μg/ml CMS via the Cell Counting Kit-8
(CCK-8) assay, the bis-AAF-R110 cell cytotoxicity assay,
Table 1 Experimental groups in vivo
Group Mouse model Test substance Route of application
1 Healthy CMS-ICC (in NaCl
solution)
Topically applied
2 Healthy NaCl-solution Topically applied
3 Atopic dermatitis CMS-ICC (in NaCl
solution)
Topically applied
4 Atopic dermatitis NaCl-solution Topically applied
5 Healthy CMS-ICC (in NaCl
solution)
Subcutaneous injection
6 Healthy NaCl-solution Subcutaneous injection
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the caspase 3/7 apoptosis assay, or the H2-DCF-DA
assay for reactive oxygen species, respectively, as de-
scribed in Additional file 1.
Statistical Analyses
Clinical and histological data are presented as mean ±
standard deviation (SD). In vitro toxicological data are
presented as mean ± standard error of the mean (SEM).
For clinical parameters, day to day differences were cal-
culated to account for different starting values at the be-
ginning of the experiment and analyzed for each day by
multiple t tests, corrected for multiple comparisons with
the Holm-Sidak method (two tailed; H0 = “means of day
to day differences are the same between CMS and ve-
hicle treated group”). For epidermal thickness, group
means were corrected for the respective untreated,
contralateral skin because of an existing systematic dif-
ference in overall epidermal thickness between the
groups. Means of corrected epidermal thickness as well
as means of mast cell and lymphocyte counts were then
analyzed using Student’s t test (two tailed; H0 = “means
of parameters are the same between CMS and vehicle
treated groups”). Eosinophil counts were analyzed using
the Kolmogorow-Smirnov two sample test, as Poisson
rather than a Gaussian distribution was assumed (two
tailed; H0 = same as above). For in vitro cytotoxicologi-
cal assays, means of all CMS concentrations and positive
controls were compared to the respective negative con-
trols using Student’s t test (one-tailed, H0 = “means of
concentrations/positive control are the same as the
negative control”). For all tests, an alpha error of 5% was
accepted.
Results
Topically Applied CMS Accumulate in the Stratum
Corneum Only
Following topical application over 5 days, both standard
fluorescence microscopy and FLIM measurements local-
ized the ICC-labeled CMS nanocarriers exclusively in
the stratum corneum of healthy hairless mice (Fig. 1a, b,
e, f ). CMS did not accumulate in the utriculi/hair
follicles.
As shown in Fig. 1g, distinct fluorescence decay curves
were extracted from the FLIM data for tissue autofluo-
rescence (cyan curve) and CMS-ICC (red curve) by the
analysis algorithm [8]. FLIM images with the corre-
sponding false color coding (Fig. 1e, f ) show a clear-cut
difference between the ICC-labeled CMS and vehicle
treated skin, underscoring the selective and highly sensi-
tive detection of labeled CMS. Thereby, FLIM analysis
confirms that the distribution of CMS-ICC is confined
to the upper layers of the stratum corneum and that the
signals can clearly be distinguished from tissue autofluo-
rescence (Fig. 1e).
Atopic Dermatitis Does Not Influence CMS Penetration
The signal pattern was identical in mice with oxazolone-
induced AD with no evidence of deeper penetration due
to inflammation-associated barrier alterations (Fig. 1c, d,
h, i). Again, distinct fluorescence decay curves could be
extracted (Fig. 1j) and FLIM images with a clear signal
to background distinction were generated to exclude
overlap with tissue autofluorescence. Nevertheless, clin-
ical data including TEWL, erythema index, and skin hy-
dration as well as histologic parameters clearly
confirmed the presence of barrier changes typically asso-
ciated with AD (Figs. 2 and 3).
CMS Are Biocompatible In Vivo
Clinical data quantification and statistical analyses failed
to reveal any statistically significant differences between
CMS-treated and solvent-treated skin in healthy as well
as AD groups. This indicates that topically applied CMS
had no detectable biological effect on normal mouse
skin or the course or severity of inflammation in the AD
model (Fig. 2).
Effects of CMS on healthy skin and the phenotype of
the AD model were further examined histopathologic-
ally. All parameters tested, which included standard
histological examination, measurement of epidermal
thickness as well as detection and quantification of CD3
+ lymphocytes, mast cells, and eosinophils, yielded no
evidence of consequences of CMS application when
compared to skin treated with vehicle alone (Fig. 3).
CMS Are Biocompatible In Vitro
No cytotoxicity of CMS, reduction in cell viability, in-
duction of apoptosis, or oxidative stress on HaCaT cells
were observed in all models employed (Fig. 4).
Mimicking Maximal Penetration of CMS Leads to Systemic
MPS Distribution Without Evidence of Toxicity
To mimic a potential transcutaneous uptake and the
resulting biodistribution and sequelae for the entire
organism, CMS were injected into the subcutaneous
tissue of healthy mice with the same time regime
used for topical dermal application. In addition to
their diffuse deposition at the injection site and the
adjacent skin, the particles were found in the local
draining lymph nodes and in cells consistent with the
mononuclear phagocytic system (MPS) in the liver,
spleen, and interalveolar septa of the lung (Fig. 5)
approx. 16 h after their last subcutaneous injection,
clearly showing that particles entered the systemic cir-
culation. Non-draining lymph nodes remained nega-
tive, suggesting that the particles did not reach all
lymphatic organs through the circulation. Further-
more, CMS were localized in the glomeruli and
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Fig. 1 (See legend on next page.)
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occasionally basolaterally to the tubular epithelial cells in
the kidney but not in any of the other organs examined.
Histopathological analyses by trained veterinary pa-
thologists (MR, HP, LM) failed to identify any pathologic
changes in the potential target organs identified (skin,
local lymph nodes, liver, spleen, lung kidney; Fig. 5) or
any of the other tissues examined.
Discussion
Our study makes two main observations: First, it sug-
gests that CMS, when applied topically to murine skin in
vivo, accumulate in the stratum corneum but do not
surmount this barrier to penetrate into the viable epider-
mis or beyond. Second, it provides evidence that the
complex skin barrier alterations associated with AD do
not result in increased penetration or otherwise altered
distribution of these nanocarriers.
Penetration of CMS Topically Applied to Healthy Skin
The local penetration pattern on healthy skin is in ac-
cordance with the only previously published results
on the penetration of topically applied CMS in vitro,
when relatively short incubation times of 6 h on ex-
cised human skin or 3 h on reconstructed human
skin were used [8]. However, in these models, CMS
penetrated into viable skin layers after prolonged in-
cubation times of 24 or 6 h, respectively [8]. It seems
likely that overhydration of the skin barrier in the
Franz cell setup due to the long contact to the water
of the acceptor compartment may have increased per-
meability in that study and contributed to this diver-
gence. Our study thus adds evidence that incubation
times of 6 or 3 h are better suited when using the re-
spective human in vitro systems to replace animal
studies for CMS-type carriers.
In addition to the skin being fully viable and in its
complete physiological environment, our study adds
three important levels of complexity to current know-
ledge derived from previous in vitro experiments: (a) a
fully functional circulatory system, (b) a fully functioning
immune system, and (c) physiological flexing and move-
ment of the skin. We were unable to detect labeled CMS
in the local lymph nodes or in any other organ which
supports our conclusion that they did not surmount the
cutaneous barrier even under conditions of physiological
tissue fluid—blood/lymph equilibrium. Furthermore,
lack of deposition in the local lymph nodes adds evi-
dence that CMS applied topically did not elicit large
scale uptake and presentation by Langerhans cells. Lang-
erhans cells are constantly sampling substances from the
internal border of the stratum corneum and thus could
(See figure on previous page.)
Fig. 1 Atopic dermatitis did not influence the dermal penetration of CMS-ICC in mice. a ICC-labeled CMS were exclusively found in the stratum
corneum of healthy mice. c This distribution pattern was virtually identical in mice with atopic dermatitis. b, d No fluorescent ICC-signals were
detected in the skin of the respective control groups. e, h FLIM analysis confirmed that CMS-ICC exclusively accumulated in the stratum corneum
in healthy mice and in mice with atopic dermatitis, based on data analysis of unique fluorescence decay curves (g, j) from tissue autofluorescence
(cyan) and from CMS-ICC (red). f, i FLIM images of vehicle-treated skin show tissue-derived autofluorescence (cyan). Fluorescence intensities in (a–d)
are adjusted to vehicle control groups and contrast-enhanced post acquisition. False color coding of the FLIM images (e, f, h, i) corresponds to the color
coding of the fluorescence decay curves (g, j). Scale bar shown in (i) refers to images (e, f, h, i) scale bar in (d) to (a–d)
Fig. 2 None of the clinical parameters tested were affected by CMS in
healthy skin or atopic dermatitis. a–d Topical application of CMS-ICC
had no visual effects on the skin of healthy mice or mice with atopic
dermatitis when compared to the solvent-treated controls. e–g Clinical
parameters transepithelial water loss (TEWL), erythema index, and skin
hydration were not significantly affected by topically applied CMS-ICC.
Note that different starting points have to be taken into account which
was addressed statistically by analyzing day to day differences rather
than absolute values. Data are presented as mean ± SD, lines connect-
ing data points are visual aids only. No statistical significances
were found
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have potentially come into broad contact with CMS [26,
27]. Finally, there is evidence that mechanical flexing of
the skin may enhance nanoparticle penetration [28, 29],
an effect not at all addressed by standard in vitro or ex
vivo models. Since mice were breathing during the hour
of incubation and moving around normally during the
rest of the time, physiological movement and stress of
the skin was depicted closer to a lifelike application.
In our setting, we were unable to detect any accumula-
tion of CMS in hair follicles/utriculi. Although hair follicle
architecture is altered in the SKH-1 mouse, this is worth
noting as hair follicles have been shown to be an import-
ant site of accumulation for certain nanoparticles [30].
No methods were available enabling us to visualize the
subcellular niche of the stratum corneum that CMS accu-
mulate in. CMS theoretically possess a hydrophilic outer
shell and they thus may be assumed to take the route
through the corneocytes. On the other hand, it seems
equally possible that they accumulate in the extracellular
lipid matrix. In non-polar environments, the outer, hydro-
philic groups of CMS have been shown to partially fold in-
ward, exposing the lipophilic inner regions and giving
them good solubility in polar solvents similar to a supra-
molecular micelle reversing its polarity [4]. In fact, the
steric arrangement of CMS may altogether be more com-
plicated than the “core-multishell” model traditionally
proposed, as the steric arrangement of the polar and non-
polar regions may not actually be shell-like. Instead, they
may rather form smaller, more randomly distributed do-
mains, which is why the particles possibly are more cor-
rectly termed multi-domain nanocarriers [4]. In light of
these findings, an intercalation of CMS particles among
(See figure on previous page.)
Fig. 3 Histological and morphometric analyses failed to reveal any effects of CMS on healthy skin or atopic dermatitis. a–d Topically applied CMS
did not alter the overall histologic appearance (a, c) or the infiltration with CD3+ T lymphocytes (b, d) in healthy mice compared to vehicle-
treated controls. e–h In the model of atopic dermatitis, the epidermis was thickened and increased infiltration of immune cells, predominantly T
lymphocytes, was observed. However, all parameters tested were unaffected by topically applied CMS when compared to vehicle-treated controls.
i–m Quantification of epidermal thickness corrected for the untreated, contralateral skin, infiltrating mast cells, CD3+ T lymphocytes, and eosino-
phils revealed no impact of CMS-ICC on healthy skin or the atopic dermatitis model. Data are presented as mean ± SD. HPF = high power field
Fig. 4 CMS exhibited good biocompatibility in vitro. a–d CMS concentrations between 50 and 700 μg/ml did not differ significantly from the
negative control (untreated cells) in cytotoxicity (bis-AAF-R110 assay), induction of apoptosis (caspase 3/7 assay), cell viability (CCK-8 assay), and
production of reactive oxygen species (H2-DCF-DA assay). Data are presented as mean ± SEM, *p < 0.05, **p < 0.005
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each other has been proposed [4]. It thus seems plausible
to assume that intercalation with the bilayers of the
stratum corneum lipid matrix is possible. In addition,
CMS are highly flexible and it has been proposed that they
may flatten down to a thickness of one nanometer [8]. On
the contrary, they may also form larger supramolecular
aggregates, depending on the solvent environment and
even loaded cargo molecules [2]. In conclusion, there is a
multitude of imaginable modes of interaction with the
stratum corneum which need further elucidation by func-
tional studies in vitro.
Penetration of CMS Topically Applied to Atopic
Dermatitis
Opposed to our initial hypothesis, the severe morpho-
logical and presumably functional barrier alterations
associated with AD [13–16, 18, 31] did not increase
the penetration of CMS past the stratum corneum.
Fig. 5 Subcutaneously injected CMS-ICC were localized in the regional lymph nodes, lung, liver, spleen, and kidney of healthy mice without any
toxic or other adverse effects. a–t Approx. 16 h after the last subcutaneous injection, CMS-ICC were predominantly found in and between cells of
the draining lymph nodes (a, arrows). Furthermore, CMS-ICC were found in the alveolar septa of the lung (e, arrow), intracellularly in cells located
within the sinusoids of the liver, consistent with Kupffer cells (i, arrow), throughout the splenic parenchyma both intracellularly and extracellularly
(m, arrow), and in the kidney, predominantly localized in the glomeruli (q, arrows).
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Although this is in accordance with CMS data from a
peeling skin disease model in vitro [8], other models
previously used to mimic diseased skin have yielded
evidence of increased CMS penetration, namely
excised human skin subjected to 30 tape strips and an
in vitro non-melanoma skin cancer model [8]. How-
ever, caution is warranted when comparing the differ-
ent models as they constitute very different
mechanisms of barrier alterations.
So far, CMS have never been investigated in AD
patients or in vivo or ex vivo models of AD. While
non-particulate substances including water and dyes
have been suggested to more effectively penetrate into
human AD skin [13–18], data on nanoparticles are
scarce. The only other nanoparticles that have been
tested in AD patients in terms of altered penetration
are zink-oxide particles which also did not surmount
the stratum corneum in three human AD volunteers
[32]. On the contrary, different zinc-oxide nanoparti-
cles did show increased penetration in a mouse model
of AD [19]. Clearly, CMS particles possess a unique
architecture with flexible side chains and variable sur-
face properties [4], largely limiting any comparisons
of our findings to the penetration behavior of other
particles, including zink oxide.
The lack of increased penetration into lesional atopic
skin has two practical implications: Most importantly, it
yields increased confidence in the biosafety of the particle
as there will be no increased contact with viable tissue, at
least under the conditions tested here. Such increased
penetration into diseased skin is always of concern for
nanoparticles [9]. On the other hand, it also means that
such an increased penetration cannot be used as a “tar-
geted delivery system” simply by having carrier and the
loaded drug preferentially penetrating into lesional skin
but not into the adjacent, healthy skin. However, as the
penetration enhancement effect of CMS on loaded drugs
does not seem to depend on the penetration of the parti-
cles themselves [8], it remains to be investigated whether
there is an effect of such a barrier alteration on the rate of
penetration enhancement by CMS.
But What About the Penetration Enhancement Effect
Shown Previously?
The CMS investigated here have previously been shown to
increase the penetration of a loaded model drug into the vi-
able skin past the stratum corneum in vitro [6–8]. Besides
making drugs soluble in a variety of solvents in a stable,
unimolecular micelle and potentially forming a drug depot
in the stratum corneum, this penetration enhancement ef-
fect is one of the main benefits sought after in the design of
the CMS. However, the aforementioned in vitro experi-
ments already showed that this penetration enhancing
effect does not seem to depend on the penetration of the
particle itself [8]. While we have not enough data yet to ef-
fectively speculate on the mechanism of this penetration
enhancement, the particles do contain long, flexible, amphi-
philic side chains containing saturated carbon chains, which
have been suggested as an ideal chemical structure for
penetration enhancement [33]. Intercalation into and modi-
fication of the lipid bilayer structure of the stratum cor-
neum extracellular matrix immediately leaps to mind.
Clearly, further studies elucidating the underlying mechan-
ism are needed. Nevertheless, whatever the mechanism
may be, this property of the particle can be seen as a very
welcome one: It has been suggested that one of the great
potential benefits of nanocarriers as penetration enhancers
may very well consist of their local action at the place
where the enhancement is needed most—the stratum cor-
neum—without penetrating themselves, as smaller mole-
cules might [34]. In any case, further studies are needed to
establish possible penetration enhancement effects in vivo
by CMS for typical anti-inflammatory drugs and a potential
therapeutic surplus value, both on healthy and barrier-
altered skin.
Biocompatibility
We also examined potential biological effects of CMS.
Both in vitro toxicological data and the systemic distri-
bution suggest acceptable biocompatibility. Nonetheless,
this is a preliminary study which was primarily designed
to investigate CMS penetration, conducted with a small
number of animals for a limited time and thus with lim-
ited statistical power in terms of biocompatibility. More-
over, it is important to consider that during topical
application small numbers of nanoparticles might reach
the dermis and get removed by venous or lymphatic
drainage without being detected by the snapshot of
microscopic particle detection [9]. The fact that we
failed to detect accumulation in the target organs we
had identified from the subcutaneous injection gives us
a little more confidence that no particles actually pene-
trated after topical application. Of course, 5 days of
application are not nearly sufficient to investigate
chronic exposure and potential long time accumulation
and that low numbers of particles below the detection
limit may have been overlooked. These questions will
have to be addressed in further, more comprehensive,
and longer-term safety studies.
General Limitations
A further limitation to this study obviously is the differ-
ence between human and murine skin [35]. Nevertheless,
it is generally accepted that the human skin is even less
penetrable than the murine skin under a variety of
circumstances [36]. Thus, our conclusion that CMS
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do not penetrate beyond the stratum corneum can
likely be transferred to human skin, until proven
otherwise.
Of equal importance, there is a great potential of
differences between the hapten-induced model of AD
used here and human AD, the etiology of which is
still incompletely understood and might include many
additional factors, such as inherited barrier dysfunc-
tions [13, 15, 16, 31, 37]. On the other hand, strong
similarities in the barrier alterations of the model
used here and human AD have been depicted [20]
and our model thus appears as among the most suit-
able and practicable models available [38].
Another limitation for our conclusions is the question
of generalizability of our results to other members of the
class of dendritic core-multishell unimolecular micelles.
Designs varying in core architecture, alkyl chain length,
bond types linking the building blocks, and surface func-
tionalization have been synthesized and are constant sub-
jects to optimization [3, 39–41]. As these particles
generally have similar size and distribution of hydrophilic
and hydrophilic compartments, however, they are ex-
pected to behave similarly in tissues. Clearly, further stud-
ies are needed to elucidate the mechanical and biological
interaction with the dermal barrier and cells to allow for a
better understanding and accurate predictions of the be-
havior of each particular carrier molecule.
Conclusions
Our in vivo data show that topically applied unimolecular
micelle core-multishell nanocarriers accumulate in the
stratum corneum of healthy skin. Importantly, no in-
creased or otherwise altered penetration was observed in
a model of atopic dermatitis, a common inflammatory
skin disorder with marked barrier disturbances. Together
with their ability to enhance penetration of even very large
model drugs previously shown in vitro, our observations
suggest that CMS may be suitable candidates for the en-
capsulation of drugs in order to release them from a
stratum corneal depot and enhance their penetration into
the viable epidermis without penetration of the carrier
and thus without biological effects by the carrier itself.
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